comparemela.com

Latest Breaking News On - Securities fraud action - Page 4 : comparemela.com

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Danimer Scientific (DNMR) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel

                                              Danimer Scientific, Inc. (NYSE: DNMR) Securities Fraud Action: The complaint alleges that Danimer made misrepresentations and omissions concerning its production of polyhydroxyalkanoate ( PHA ) – a biodegradeable alternative to petrochemical-based plastics, which the company sells under its proprietary Nodax brand for usage in water bottles, straws, and food containers. The truth emerged over a series of disclosures, beginning on Mar. 20, 2021, when the  Wall Street Journal questioned whether Nodax s breaks down far more quickly than fossil-fuel plastics, finding many claims about Nodax s are exaggerated and misleading. One plastics expert labeled Danimer s claims about Nodax s biodegradability as not accurate and as greenwashing.   Next, on Apr. 22, 2021 analyst

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages PureCycle Technologies (PCT) Investors to Contact Firm s Attorneys Now, Securities Fraud Case Filed

HAGENS BERMAN Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel

                                             FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen s presentation of false data of roxadustat to make the anemia drug look safer than it is. Throughout the Class Period, FibroGen touted the prospects of roxadustat. A key selling point for the drug was its purported heart safety as compared to standard of care erythropoietin (EPO) injectable therapies, which cannot be proscribed to a variety of patients at risk of major cardiac events. To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other at risk populations, in incident dialysis patients.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Canaan (CAN) Investors with Losses to Contact Its Attorneys Now, Securities Class Action Filed, Application Deadline Established

Home / Top News / HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Canaan (CAN) Investors with Losses to Contact Its Attorneys Now, Securities Class Action Filed, Application Deadline Established HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Canaan (CAN) Investors with Losses to Contact Its Attorneys Now, Securities Class Action Filed, Application Deadline Established SAN FRANCISCO, May 08, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Canaan Inc. (NASDAQ: CAN) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Feb. 10, 2021 – Apr. 9, 2021 Lead Plaintiff Deadline: June 14, 2021 Visit: www.hbsslaw.com/investor-fraud/CAN 844-916-0895

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.